|
1.
|
|
10 p, 496.7 KB |
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma : IKEMA subgroup analysis
/
Facon, Thierry (Lille University Hospital) ;
Moreau, Philippe (University of Nantes) ;
Martin, Thomas G. (University of California San Francisco) ;
Spicka, Ivan (Charles University and General Hospital, Prague, Czech Republic) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Koh, Youngil (Seoul National University Hospital, South Korea) ;
Lim, Andrew (Austin & Repatriation Medical Center, Heidelberg, Victoria, Australia) ;
Mikala, Gabor (South Pest Central Hospital, Budapest, Hungary) ;
Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ;
Yağci, Münci (Gazi University, Ankara, Turkey) ;
Cavo, Michele (Bologna University School of Medicine, Italy) ;
Yong, Kwee (University College Hospital, London, UK) ;
Risse, Marie Laure (Sanofi R&D, Vitry-Sur-Seine, France) ;
Asset, Gaëlle (Sanofi R&D, Chilly-Mazarin, France) ;
Schwab, Sandrine (Sanofi R&D, Chilly-Mazarin, France) ;
Martinez, Gracia (Hospital das Clínicas de São Paulo, Brazil)
In this subgroup analysis of the randomized, Phase 3 IKEMA study (NCT03275285), we evaluated efficacy and safety of the anti-CD38 monoclonal antibody isatuximab (Isa) in combination with carfilzomib-dexamethasone (Isa-Kd) versus Kd in older (≥70 years of age, n = 86) and younger (<70 years, n = 216) patients with relapsed multiple myeloma (MM). [...]
2022 -  10.1002/hon.3038
Hematological Oncology, Vol. 40 Núm. 5 (december 2022) , p. 1020-1029
|
|
|
2.
|
|
9 p, 1.5 MB |
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma : updated results from IKEMA, a randomized Phase 3 study
/
Martin, Thomas (University of California at San Francisco, USA) ;
Dimopoulos, Meletios (University of Athens, Greece) ;
Mikhael, Joseph (Translational Genomics Research Institute. City of Hope Cancer Center, Phoenix, USA) ;
Yong, Kwee (University College Hospital, London, UK) ;
Capra, Marcelo (Centro Integrado de Hematologia e Oncologia. Hospital Mãe de Deus, Porto Alegre, Brazil) ;
Facon, Thierry (Lille University Hospital, France) ;
Hajek, Roman (University of Ostrava, Czech Republic) ;
Špička, Ivan (Department of Hematology. 1st Faculty of Medicine. Charles University and General Hospital, Prague, Czech Republic) ;
Baker, Ross (Murdoch University, Perth, Australia) ;
Kim, Kihyun (Sungkyunkwan University School of Medicine, Seoul, South Korea) ;
Martinez, Gracia (Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil) ;
Min, Chang-Ki (The Catholic University of Korea) ;
Pour, Ludek (University Hospital Brno (República Txeca)) ;
Leleu, Xavier (Service d'Hématologie et Thérapie Cellulaire. CHU and CIC Inserm, France) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Koh, Youngil (Seoul National University Hospital, Seoul, South Korea) ;
Suzuki, Kenshi (Japanese Red Cross Medical Center, Tokyo, Japan) ;
Casca, France (Ividata Life Science, Levallois-Perret, France) ;
Macé, Sandrine (Sanofi, R&D, Chilly-Mazarin, France) ;
Risse, Marie-Laure (Sanofi, R&D, Vitry-sur-Seine, France) ;
Moreau, Philippe (University Hospital Hôtel-Dieu, Nantes, France)
Longer-term outcomes with the anti-CD38 antibody isatuximab in combination with carfilzomib-dexamethasone (Isa-Kd) were evaluated in the randomized Phase 3 trial IKEMA (NCT03275285), in a prespecified, follow-up analysis of progression-free survival (PFS, primary study endpoint), final complete response (CR) using Hydrashift Isa immunofixation assay, minimal residual disease (MRD) negativity, and safety. [...]
2023 - 10.1038/s41408-023-00797-8
Blood Cancer Journal, Vol. 13 Núm. 1 (december 2023)
|
|
|
3.
|
|
9 p, 982.6 KB |
Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics : IKEMA subgroup analysis
/
Spicka, Ivan (Charles University and General Hospital) ;
Moreau, Philippe (University of Nantes) ;
Martin, Thomas G. (University of California San Francisco) ;
Facon, Thierry (Lille University Hospital) ;
Martínez, Gracia (Hospital das Clínicas de Faculdade de Medicina da Universidade de São Paulo) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Koh, Youngil (Seoul National University Hospital) ;
Lim, Andrew (Austin and Repatriation Medical Center) ;
Mikala, Gabor (South Pest Central Hospital) ;
Rosiñol, Laura (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Yağci, Münci (Gazi University) ;
Cavo, Michele (Università di Bologna) ;
Risse, Marie-Laure (Sanofi (França)) ;
Asset, Gaëlle (Sanofi (França)) ;
Macé, Sandrine (Sanofi (França)) ;
Van de Velde, Helgi (Sanofi) ;
Yong, Kwee (University College Hospital) ;
Universitat Autònoma de Barcelona
Introduction: The presence of high-risk chromosomal abnormalities [t(4;14), del(17p), and t(14;16)] has been linked with inferior outcomes in patients with multiple myeloma (MM). A prespecified interim analysis of the Phase 3 IKEMA study (NCT03275285) demonstrated that isatuximab (Isa) + carfilzomib (K) and dexamethasone (d; Isa-Kd) significantly improved progression-free survival (PFS) versus Kd in patients with relapsed MM. [...]
2022 - 10.1111/ejh.13835
European Journal of Haematology, Vol. 109 Núm. 5 (november 2022) , p. 504-512
|
|
|
4.
|
|
13 p, 861.9 KB |
Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation : The phase III TOURMALINE-MM4 trial
/
Dimopoulos, Meletios (The National and Kapodistrian University of Athens) ;
Špička, I. (Charles University. Faculty of Medicine in Hradec Králové) ;
Quach, H. (St Vincent's Hospital (Sydney)) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Hájek, R. (Department of Hemato-oncology. University Hospital Ostrava. University of Ostrava. Faculty of Medicine) ;
Garg, M. (Leicester General Hospital (Leicester, Regne Unit)) ;
Beksac, M. (Department of Hematology. Ankara University) ;
Bringhen, S. (Division of Hematology. University of Torino. Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino) ;
Katodritou, E. (Department of Hematology. Theagenion Cancer Hospital) ;
Chng, W. J. (Department of Hematology-Oncology. National University Cancer Institute. National University Health System. Yong Loo Lin School of Medicine. Cancer Science Institute of Singapore. National University of Singapore) ;
Leleu, Xavier (Pôle Régional de Cancérologie. Department of Haematology. Centre Hospitalier Universitaire La Milétrie-Poitiers) ;
Iida, S. (Department of Hematology and Oncology. Nagoya City University. Graduate School of Medical Sciences) ;
Mateos, M. V. (Hospital Universitario de Salamanca. Centro de Investigación del Cáncer) ;
Morgan, G. (Perlmutter Cancer Center. NYU Langone Health) ;
Vorog, A. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ;
Labotka, R. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ;
Wang, B. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ;
Palumbo, A. (Millennium Pharmaceuticals. Inc.. Takeda Pharmaceutical Company Limited) ;
Lonial, S. (Department of Hematology and Medical Oncology. Winship Cancer Institute of Emory University) ;
Universitat Autònoma de Barcelona
PURPOSE Maintenance therapy prolongs progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM) not undergoing autologous stem cell transplantation (ASCT) but has generally been limited to immunomodulatory agents. [...]
2020 - 10.1200/JCO.20.02060
Journal of Clinical Oncology, Vol. 38 Núm. 34 (january 2020) , p. 4030-4041
|
|
|
5.
|
|
8 p, 354.8 KB |
A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
/
Hájek, R (Faculty of Medicine. University of Ostrava) ;
Pour, L. (University Hospital Brno (República Txeca)) ;
Ozcan, M. (Ankara University School of Medicine) ;
Martin Sánchez, J. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
García Sanz, R. (Hospital Universitario de Salamanca) ;
Anagnostopoulos, Achilles (George Papanicolaou General Hospital (Tessalònia, Grècia)) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Cascavilla, N. (Istituto di Ricovero e Cura A Carattere Scientifico (IRCCS)) ;
Terjung, A. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ;
Lee, Y. (Pharmacyclics LLC. an AbbVie Company) ;
Briso, E. M. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ;
Dobkowska, E. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ;
Hauns, B. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ;
Špička, I. (Charles University. Faculty of Medicine in Hradec Králové) ;
Universitat Autònoma de Barcelona
Objective: We evaluated ibrutinib, a once-daily inhibitor of Bruton's tyrosine kinase, combined with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who had received 1-3 prior therapies. [...]
2020 - 10.1111/ejh.13377
European Journal of Haematology, Vol. 104 Núm. 5 (january 2020) , p. 435-442
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
